Genmab Acquires Targeted Antibodies from iDD Biotech, While Opting out of its Co-Development Option with ADC Therapeutics

Genmab A/s is altering its pipeline, announcing that the company has agreed to acquire three pre-clinical stage targeted antibodies from iDD Biotech and the company’s decision to drop the option to co-develop HuMax-TAC-ADC with ADC Therapeutics Sarl.

Genmab said that it has entered into an agreement to purchase antibodies and related patents and know-how from iDD Biotech. These antibodies are directed to DR5, also known as Trail Receptor 2 (TRAIL-R2), an emerging cancer target. Genmab will pay iDD €2.5 million upfront, and future potential milestone payments ranging from €3.5 million to potentially €101.5 million.

“We are pleased to add this exciting target and these unique DR5 antibodies to our expanding list of pre-clinical assets. This move provides Genmab with another opportunity to create potential next-generation antibody drugs which could lead to new ways of treating cancer,” said Jan van de Winkel, PhD, Chief Executive Officer of Genmab.

Genmab said that the acquisition of antibody assets is synergistic with its strategy to create a broad pipeline of differentiated therapeutic products and to leverage its antibody expertise to create leapfrog drugs.

The news came days after Genmab announced its decision not to exercise the co-development right for HuMax-TAC-ADC under its agreement with ADC Therapeutics. Under the terms of the companies’ agreement Genmab had a 50 percent ownership stake with an option to maintain equal ownership prior to the submission of an investigational new drug (IND) application and fund half of the development costs. Genmab decided not to retain its co-development right, but will retain a 25 percent ownership stake in the product.

HuMax-TAC-ADC is an ADC combining Genmab’s HuMax-TAC antibody and ADC Therapeutics’ PBD-based warhead and linker technology. It targets CD25, which is expressed on a variety of hematological tumors and shows limited expression on normal tissues, which makes it a very attractive target for antibody-payload approaches. HuMax-TAC-ADC has the potential to be a first-in-class antibody drug conjugate for the treatment of CD25-expressing lymphomas and leukemias.

“While we have decided not to fund co-development of HuMax-TAC-ADC with ADC Therapeutics, we are pleased to still have 25% of the rights to the product, which has potential to become a first-in-class antibody-drug conjugate therapeutic in certain hematological cancer indications,” said Jan van de Winkel.

Source: Genmab A/S

Last updated: 3/19/15; 1:55pm EST

Check Also

FDA Approves Gavreto for the Treatment of Adults with Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: …

Leave a Reply

Your email address will not be published. Required fields are marked *